Areas of Focus
- Anti-inflammatory immunopharmacology, Molecular pharmacology
- Discovery of marine biofunctional molecules and innovative drug research and development
- Discovery and confirmation of new drug targets
Work Experience
- Part-time PI at Tongji University Affiliated Tenth People's Hospital
- Chief Scientist at Innovative Drug Research Center of Baijiayi Pharmaceutical Co., Ltd.
- Committee Member of Biochemical and Biotechnological Drugs at Chinese Pharmaceutical Association
- Expert in Novel Coronavirus Pneumonia Treatment Drug Advisory Group at National Health Commission
Academic Background & Achievements
- Doctorate: Not specified
- Hosted 12 major projects including national key research plans
- Co-edited 5 monographs
- Holds 6 national invention patents
Publications
- Recombinant expression, purification and bioactivity characterization of extracellular domain of human tumor necrosis factor receptor 1, Yiming Lu et al., 2019
- Cloning, expression, purification and bioactivity evaluation of a thrombin-like enzyme from Deinagkistrodon acutus venom gland library, Yiming Lu et al., 2018
- SHP2 associates with nuclear localization of STAT3: the significance in progression and prognosis of colorectal cancer, Yiming Lu et al., 2017
- Hydrostatin-SN1, a sea snake-derived bioactive peptide, reduces inflammation in a mouse model of acute lung injury, Yiming Lu et al., 2017
- Hydrostatin-TL1, an Anti-Inflammatory Active Peptide from the Venom Gland of Hydrophis cyanocinctus in the South China Sea, Yiming Lu et al., 2016
- Screening of an anti-inflammatory peptide from Hydrophis cyanocinctus and analysis of its activities and mechanism in DSS-induced acute colitis, Yiming Lu et al., 2016
- Enhancement of immunogenic response and protection in model rats by CSTM nanoparticles anticaries DNA vaccine, Yiming Lu et al., 2016
Awards
- 2016 Shanghai Technology Invention Third Prize (2nd place)
